PEI Regulatory Approval Received for Government Funded (€ 7.4 Million) Clinical Trial Investigating Adrenomed’s Adrecizumab in Treating Endothelial Barrier Dysfunction in Hospitalized COVID-19 Patients

Adrenomed AG announced that its proprietary sepsis drug candidate Adrecizumab received a funding commitment of € 7.4 million from the German Federal Ministry of Education and Research as part of the German funding initiatives for the clinical development of COVID-19 drugs and their manufacturing capabilities.